NEW YORK (GenomeWeb) – Takeda Pharmaceutical today announced it has signed a partnership with Sanford-Burnham Medical Research Institute to study the role of gene regulatory proteins as targets for the treatment of heart failure.

The partners will screen and develop molecules that may improve the metabolism and function of a damaged heart. Sanford-Burnham and Takeda scientists will collaborate to validate the targets and molecules with a goal of creating new treatments for heart failure.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.